Regeneron

About Regeneron

Regeneron is a leading biotechnology company that discovers, develops, and commercialises innovative medicines for the treatment of serious diseases. Founded in 1988, the company has a strong commitment to scientific research and development, which has led to the creation of numerous breakthrough therapies.

With a focus on areas such as ophthalmology, oncology, immunology, and cardiovascular diseases, Regeneron aims to address unmet medical needs and improve patient outcomes. The company’s flagship product, EYLEA, is a treatment for various eye diseases and has significantly changed the landscape of ophthalmic care.

Regeneron employs a unique VelociSuite® technology platform, which accelerates the drug discovery process by enabling the rapid generation of fully human monoclonal antibodies. This innovative approach has resulted in a robust pipeline of potential therapies that are currently in various stages of clinical development.

The company is headquartered in Tarrytown, New York, but has a growing presence in the UK, where it collaborates with local research institutions and healthcare providers. Regeneron is dedicated to fostering partnerships that enhance its research capabilities and expand access to its therapies.

In addition to its commitment to innovation, Regeneron places a strong emphasis on corporate responsibility. The company actively engages in initiatives that promote sustainability, diversity, and community health. Through these efforts, Regeneron strives to make a positive impact on society while advancing the field of medicine.

As a testament to its success, Regeneron has received numerous awards and recognitions for its contributions to science and healthcare. The company continues to push the boundaries of what is possible in biotechnology, driven by a vision to transform the lives of patients around the world.